Skip to main content
PMC home page
Gut logoLink to Gut
. 2000 Mar;46(3):420–426. doi: 10.1136/gut.46.3.420

Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B

G Fattovich 1, G Giustina 1, E Christensen 1, M Pantalena 1, I Zagni 1, G Realdi 1, S Schalm 1
PMCID: PMC1727859  PMID: 10673308

Abstract

BACKGROUND—The effect of hepatitis delta virus (HDV) infection on the clinical course of cirrhosis type B is poorly defined.
AIMS—To investigate the impact of HDV status on morbidity and mortality in cirrhosis type B.
PATIENTS/METHODS—Retrospective cohort study of 200 Western European patients with compensated cirrhosis type B followed for a median period of 6.6 years.
RESULTS—At diagnosis, 20% of patients had antibodies to HDV (anti-HDV); median age was lower in anti-HDV positive cirrhotics (34 v 48 years respectively). Kaplan-Meier five year probability of hepatocellular carcinoma (HCC) was 6, 10, and 9% in anti-HDV positive/HBeAg negative, anti-HDV negative/HBeAg negative, and anti-HDV negative/HBeAg positive cirrhotics respectively; the corresponding figures for decompensation were 22, 16, and 19% and for survival they were 92, 89, and 83% respectively. Cox regression analysis identified age, albumin concentration, γ-globulin concentration, and HDV status as significant independent prognostic variables. After adjustment for clinical and serological differences at baseline, the risk (95% confidence interval) for HCC, decompensation, and mortality was increased by a factor of 3.2 (1.0 to 10), 2.2 (0.8 to 5.7), and 2.0 (0.7 to 5.7) respectively in anti-HDV positive relative to HDV negative cirrhotic patients. The adjusted estimated five year risk for HCC was 13, 4, and 2% for anti-HDV positive/HBeAg negative, anti-HDV negative/HBeAg negative, and anti-HDV negative/HBeAg positive cirrhotics respectively; the corresponding figures for decompensation were 18, 8, and 14% and for survival 90, 95, and 93% respectively.
CONCLUSIONS—HDV infection increases the risk for HCC threefold and for mortality twofold in patients with cirrhosis type B.


Keywords: delta hepatitis; prognosis; hepatocellular carcinoma; decompensation; survival

Full Text

The Full Text of this article is available as a PDF (171.4 KB).

Figure 1  .

Figure 1  

Open in a new tab

Cumulative probability of hepatocellular carcinoma (HCC) appearance in patients with compensated cirrhosis type B (Child A) in relation to anti-hepatitis delta virus (HDV) and hepatitis B e antigen (HBeAg) status. The five year appearance rate was 6, 10, and 9% for anti-HDV positive/HBeAg negative (thick line), anti-HDV negative/HBeAg negative (thin line), and anti-HDV negative/HBeAg positive (dashed line) patients respectively (p = 0.33, log rank test) (top). The estimated five year probability adjusted for all potential prognostic variables by Cox model was 13, 4, and 2% for anti-HDV positive/HBeAg negative, anti-HDV negative/HBeAg negative, and anti-HDV negative/HBeAg positive patients respectively (bottom).

Figure 2  .

Figure 2  

Open in a new tab

Cumulative probability of developing decompensation in patients with compensated cirrhosis type B (Child A) in relation to anti-hepatitis delta virus (HDV) and hepatitis B e antigen (HBeAg) status. The analysis included 171 patients who remained tumour free. The five year probability of decompensation was 22, 16, and 19% for anti-HDV positive/HBeAg negative (thick line), anti-HDV negative/HBeAg negative (thin line), and anti-HDV negative/HBeAg positive (dashed line) patients (p = 0.38, log rank test) (top). The estimated five year probability adjusted for all potential prognostic variables by Cox model was 18, 8, and 14% for anti-HDV positive/HBeAg negative, anti-HDV negative/HBeAg negative, and anti-HDV negative/HBeAg positive patients respectively (bottom).

Figure 3  .

Figure 3  

Open in a new tab

Cumulative survival probability in patients with compensated cirrhosis type B (Child A) in relation to anti-hepatitis delta virus (HDV) and hepatitis B e antigen (HBeAg) status. The five year survival probability was 92, 89, and 83% for anti-HDV positive/HBeAg negative (thick line), anti-HDV negative/HBeAg negative (thin line), and anti-HDV negative/HBeAg positive (dashed line) patients (p = 0.61, log rank test) (top). The estimated five year survival probability adjusted for all potential prognostic variables by Cox model was 90, 95, and 93% for anti-HDV positive/HBeAg negative, anti-HDV negative/HBeAg negative, and anti-HDV negative/HBeAg positive patients respectively (bottom).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acute and chronic hepatitis revisited. Review by an international group. Lancet. 1977 Oct 29;2(8044):914–919. [PubMed] [Google Scholar]
  2. Bonino F., Negro F., Baldi M., Brunetto M. R., Chiaberge E., Capalbo M., Maran E., Lavarini C., Rocca N., Rocca G. The natural history of chronic delta hepatitis. Prog Clin Biol Res. 1987;234:145–152. [PubMed] [Google Scholar]
  3. Caredda F., Rossi E., d'Arminio Monforte A., Zampini L., Re T., Meroni B., Moroni M. Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome. J Infect Dis. 1985 May;151(5):925–928. doi: 10.1093/infdis/151.5.925. [DOI] [PubMed] [Google Scholar]
  4. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology. 1987 Nov-Dec;7(6):1346–1358. doi: 10.1002/hep.1840070628. [DOI] [PubMed] [Google Scholar]
  5. Colombo M., Cambieri R., Rumi M. G., Ronchi G., Del Ninno E., De Franchis R. Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis. Gastroenterology. 1983 Aug;85(2):235–239. [PubMed] [Google Scholar]
  6. Fattovich G., Boscaro S., Noventa F., Pornaro E., Stenico D., Alberti A., Ruol A., Realdi G. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis. 1987 May;155(5):931–935. doi: 10.1093/infdis/155.5.931. [DOI] [PubMed] [Google Scholar]
  7. Genesca J., González A., Torregrosa M., Mujal A., Segura R. High levels of endotoxin antibodies contribute to hyperglobulinemia of cirrhotic patients. Am J Gastroenterol. 1998 Apr;93(4):664–665. doi: 10.1111/j.1572-0241.1998.664_b.x. [DOI] [PubMed] [Google Scholar]
  8. Govindarajan S., Kanel G. C., Peters R. L. Prevalence of delta-antibody among chronic hepatitis B virus infected patients in the Los Angeles area: its correlation with liver biopsy diagnosis. Gastroenterology. 1983 Jul;85(1):160–162. [PubMed] [Google Scholar]
  9. Hadziyannis S. J., Sherman M., Lieberman H. M., Shafritz D. A. Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers. Hepatology. 1985 Jul-Aug;5(4):544–547. doi: 10.1002/hep.1840050404. [DOI] [PubMed] [Google Scholar]
  10. Peto R., Pike M. C. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics. 1973 Sep;29(3):579–584. [PubMed] [Google Scholar]
  11. Realdi G., Fattovich G., Hadziyannis S., Schalm S. W., Almasio P., Sanchez-Tapias J., Christensen E., Giustina G., Noventa F. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1994 Oct;21(4):656–666. doi: 10.1016/s0168-8278(94)80115-0. [DOI] [PubMed] [Google Scholar]
  12. Rizzetto M. The delta agent. Hepatology. 1983 Sep-Oct;3(5):729–737. doi: 10.1002/hep.1840030518. [DOI] [PubMed] [Google Scholar]
  13. Rizzetto M., Verme G., Recchia S., Bonino F., Farci P., Aricò S., Calzia R., Picciotto A., Colombo M., Popper H. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med. 1983 Apr;98(4):437–441. doi: 10.7326/0003-4819-98-4-437. [DOI] [PubMed] [Google Scholar]
  14. Sagnelli E., Felaco F. M., Filippini P., Pasquale G., Peinetti P., Buonagurio E., Aprea L., Pulella C., Piccinino F., Giusti G. Influence of HDV infection on clinical, biochemical and histological presentation of HBsAg positive chronic hepatitis. Liver. 1989 Aug;9(4):229–234. doi: 10.1111/j.1600-0676.1989.tb00404.x. [DOI] [PubMed] [Google Scholar]
  15. Sagnelli E., Stroffolini T., Ascione A., Bonino F., Chiaramonte M., Colombo M., Craxi A., Giusti G., Manghisi O. G., Pastore G. The epidemiology of hepatitis delta infection in Italy. Promoting Group. J Hepatol. 1992 May;15(1-2):211–215. doi: 10.1016/0168-8278(92)90038-q. [DOI] [PubMed] [Google Scholar]
  16. Triger D. R., Wright R. Hyperglobulinaemia in liver disease. Lancet. 1973 Jun 30;1(7818):1494–1496. doi: 10.1016/s0140-6736(73)91827-8. [DOI] [PubMed] [Google Scholar]
  17. Wu J. C., Lee S. D., Govindarajan S., Kung T. W., Tsai Y. T., Lo K. J., Ting L. P. Correlation of serum delta RNA with clinical course of acute hepatitis delta virus superinfection in Taiwan: a longitudinal study. J Infect Dis. 1990 Jun;161(6):1116–1120. doi: 10.1093/infdis/161.6.1116. [DOI] [PubMed] [Google Scholar]
  18. de Man R. A., Sprey R. P., Niesters H. G., Heijtink R. A., Zondervan P. E., Hop W., Schalm S. W. Survival and complications in a cohort of patients with anti-delta positive liver disease presenting in a tertiary referral clinic. J Hepatol. 1995 Dec;23(6):662–667. doi: 10.1016/0168-8278(95)80031-x. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES